Telephone
61.8.8209.2666
Address
Salisbury South 1538 Main North Road Salisbury, South Australia (SA) 5106
Description
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 2.68 - 5.77
Trade Value (12mth)
AU$281,213.00
1 week
7.35%
1 month
49.19%
YTD
50.31%
1 year
50.31%
All time high
37.0985
EPS 3 yr Growth
N/A
EBITDA Margin
-65.90%
Operating Cashflow
-$43m
Free Cash Flow Return
-7.00%
ROIC
-51.30%
Interest Coverage
-11.60
Quick Ratio
1.50
Shares on Issue (Fully Dilluted)
83m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
2.15
Date | Announcements |
---|---|
31 May 23 |
Update - Notification of buy-back - MYX
×
Update - Notification of buy-back - MYX |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 March 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
31 July 23 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
31 August 23 |
Preliminary Final Report
×
Preliminary Final Report |
31 August 23 |
2023 Full Year Results Media Release
×
2023 Full Year Results Media Release |
31 August 23 |
2023 Full Year Results Investor Presentation
×
2023 Full Year Results Investor Presentation |
31 August 22 |
Non-Executive Director appointment and retirement
×
Non-Executive Director appointment and retirement |
31 August 22 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
31 August 11 |
FY11 Financial Results Presentation
×
FY11 Financial Results Presentation |
31 August 10 |
F10 Financial Results Presentation (HGN-AU)
×
F10 Financial Results Presentation (HGN-AU) |
30 November 23 |
Update - Notification of buy-back - MYX
×
Update - Notification of buy-back - MYX |
30 November 23 |
AGM presentation and business update
×
AGM presentation and business update |
30 November 23 |
Chair's Address to Shareholders
×
Chair's Address to Shareholders |
30 November 23 |
Update on US Department of Justice investigation
×
Update on US Department of Justice investigation |
30 November 23 |
Results of Meeting
×
Results of Meeting |
30 November 23 |
Mayne Pharma announces change of auditor
×
Mayne Pharma announces change of auditor |
30 November 23 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
30 November 22 |
AGM presentation and business and trading update
×
AGM presentation and business and trading update |
30 November 22 |
Chairman's Address to Shareholders
×
Chairman's Address to Shareholders |
30 November 22 |
Results of Meeting
×
Results of Meeting |
30 May 23 |
Update - Notification of buy-back - MYX
×
Update - Notification of buy-back - MYX |
30 March 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
30 March 23 |
Notification of buy-back - MYX
×
Notification of buy-back - MYX |
30 June 23 |
Update - Notification of buy-back - MYX
×
Update - Notification of buy-back - MYX |
30 June 23 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
30 December 22 |
Section 708A cleansing notice
×
Section 708A cleansing notice |
29 September 23 |
Notification regarding unquoted securities - MYX
×
Notification regarding unquoted securities - MYX |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.